Advanced 64 Cu/ 67 Cu-Based Theranostics: Application of the Copper Chelator TE1PA to a Murine Model of HER2-Positive Gastric Cancer
Inorganic Chemistry · 23.06.2025 · 64 (24) · 12189-12197
DOI: 10.1021/acs.inorgchem.5c01513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inorganic Chemistry, online erschienen am 10.06.2025. Verfasst von Julie Pineau und 5 weiteren Autor:innen. Beteiligte Einrichtung: Univ Brest, UMR CNRS 6521 CEMCA, 6 Avenue Victor le Gorgeu, 29238 Brest, France. Hauptthemen laut MEDLINE: Stomach Neoplasms, Copper Radioisotopes, Erb-b2 Receptor Tyrosine Kinases, Chelating Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Jean-Marc Herbert, SATT Ouest Valorisation.
Abstract (Originalsprache)
The development of 64Cu/67Cu-based theranostic probes addresses the need for integrated cancer diagnosis and therapy. To target HER2-positive gastric cancer, trastuzumab was conjugated to p-SCN-Bn-TE1PA (DOL of 1.1-2.0), achieving high yields and purity. Binding assays on BT-474 cells confirmed the preserved cellular uptake of the bioconjugate. The successful radiolabeling of Trastuzumab-p-SCN-Bn-TE1PA (DOL of 2) with both the 64Cu- and 67Cu-isotopes demonstrated suitability for in vivo studies. In a preclinical model of HER2-positive gastric cancer, [64Cu]Cu-Trastuzumab-p-SCN-Bn-TE1PA enabled effective PET imaging with tumor-specific uptake (>21%IA/g) and clearance through the spleen, liver and kidneys. Therapeutic studies with [67Cu]Cu-Trastuzumab-p-SCN-BnTE1PA (10-20 MBq) demonstrated dose-dependent tumor inhibition of growth, without toxicity or adverse health effects. This work exemplifies the clinical potential of associating 64Cu-imaging and 67Cu-therapy. By combining a robust isotopic pair, a customized bifunctional chelator and trastuzumab, this study demonstrates a promising approach for HER2-positive gastric cancer treatment in nuclear medicine, paving the way for personalized copper-based theranostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Univ Brest, UMR CNRS 6521 CEMCA, 6 Avenue Victor le Gorgeu, 29238 Brest, France.
- Oncodesign Services, 20 Rue Jean Mazen, 21000 Dijon, France.
ORCID-Profile: Raphaël Tripier
Förderung
- Jean-Marc Herbert
- SATT Ouest Valorisation
Zitieren
APA
Pineau, J., Ollier, C., Mothes, C., Belderbos, S., Le Bris, N., & Tripier, R. (2025). Advanced 64 Cu/ 67 Cu-Based Theranostics: Application of the Copper Chelator TE1PA to a Murine Model of HER2-Positive Gastric Cancer. Inorganic Chemistry, 64(24), 12189-12197. https://doi.org/10.1021/acs.inorgchem.5c01513
Vancouver
Pineau J, Ollier C, Mothes C, Belderbos S, Le Bris N, Tripier R. Advanced 64 Cu/ 67 Cu-Based Theranostics: Application of the Copper Chelator TE1PA to a Murine Model of HER2-Positive Gastric Cancer. Inorganic Chemistry. 2025;64(24):12189-12197. doi:10.1021/acs.inorgchem.5c01513
BibTeX
@article{Pineau2025,
author = {Pineau, Julie and Ollier, Cédric and Mothes, Céline and Belderbos, Sarah and Le Bris, Nathalie and Tripier, Raphaël},
title = {Advanced 64 Cu/ 67 Cu-Based Theranostics: Application of the Copper Chelator TE1PA to a Murine Model of HER2-Positive Gastric Cancer},
journal = {Inorganic Chemistry},
year = {2025},
volume = {64},
number = {24},
pages = {12189--12197},
doi = {10.1021/acs.inorgchem.5c01513}
}
EUVIMED